<DOC>
	<DOCNO>NCT00612885</DOCNO>
	<brief_summary>The main objective PMS study monitor assess safety Mobic® intramuscular injection ( 7.5mg ~ 15mg , q.d . ) 3 day ( case need prolong treatment , switch Mobic® capsule therapy possible ) Korean patient osteoarthritis rheumatoid arthritis .</brief_summary>
	<brief_title>Safety Efficacy Mobic Inj . ( Meloxicam ) Patients With OA RA : Observational Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<criteria>INCLUSION CRITERIA : diagnose osteoarthritis rheumatoid arthritis EXCLUSION CRITERIA : 1 . Known hypersensitivity meloxicam 2 . Cross hypersensitivity aspirin nonsteroidal antiinflammatory drug 3 . Symptoms asthma , rhinitis , angioneurotic edema , urticaria follow administration aspirin NSAIDs 4 . Active peptic ulceration 5 . Severe hepatic failure . 6 . Nondialysed severe renal insufficiency 7 . Children adolescent age 15 year less 8 . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>